Piddybull. schreef op 6 april 2022 18:38:
Details GSK deal :
From the news release
Nov 22, 2021:Under the terms of the agreement, Arrowhead will receive an upfront payment of $120 million and is eligible for additional payments of
$30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to Arrowhead of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments. Arrowhead is further eligible to receive tiered royalties on net product sales.
ARWR wordt een heus cash machine !!
Je merkt het vandaag wel nog niet in de koersvorming.
Even geduld, komt dik in orde.